Hualan Biological Vaccine Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Hualan Biological Vaccine has a total shareholder equity of CN¥6.1B and total debt of CN¥300.0M, which brings its debt-to-equity ratio to 4.9%. Its total assets and total liabilities are CN¥7.6B and CN¥1.5B respectively. Hualan Biological Vaccine's EBIT is CN¥444.9M making its interest coverage ratio -5.3. It has cash and short-term investments of CN¥2.5B.
Belangrijke informatie
4.9%
Verhouding schuld/eigen vermogen
CN¥300.00m
Schuld
| Rente dekkingsratio | -5.3x |
| Contant | CN¥2.54b |
| Aandelen | CN¥6.09b |
| Totaal verplichtingen | CN¥1.55b |
| Totaal activa | CN¥7.64b |
Recente financiële gezondheidsupdates
Recent updates
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly
Oct 08
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk
Jul 25Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's
Jun 11Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)
Apr 03Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next
Apr 02Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity
Apr 01An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued
Mar 04Analyse van de financiële positie
Kortlopende schulden: 301207's short term assets (CN¥4.6B) exceed its short term liabilities (CN¥1.5B).
Langlopende schulden: 301207's short term assets (CN¥4.6B) exceed its long term liabilities (CN¥44.2M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 301207 has more cash than its total debt.
Schuld verminderen: 301207's debt to equity ratio has increased from 0% to 4.9% over the past 5 years.
Schuldendekking: 301207's debt is well covered by operating cash flow (250%).
Rentedekking: 301207 earns more interest than it pays, so coverage of interest payments is not a concern.